MedImmune boosts cancer R&D pipeline with potential $440M Spirogen buy

10/15/2013 | Reuters

AstraZeneca's MedImmune unit agreed to acquire Spirogen, a privately held biotech firm focused on antibody-drug conjugate technology, for $200 million upfront plus $240 million in milestone fees as part of efforts to strengthen its oncology research and development pipeline. The agreement includes a $20 million equity investment in Switzerland's ADC Therapeutics, which has a licensing deal with Spirogen. ADC's and Spirogen's technologies will allow MedImmune to "accelerate antibody-drug conjugates into the clinic," MedImmune Executive Vice President Bahija Jallal said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL